Aberdeen Group’s Soleno Therapeutics SLNO Stock Holding History

Aberdeen Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-287,456	Closed	-$9.62M	–	968
2026 Q1	$9.62M	Hold	287,456	–	–	0.02%	596
2025 Q4	$13.3M	Buy	+287,456	New	+$15.8M	0.02%	552

Aberdeen Group's SLNO Position: Q2 2026 in Review

Aberdeen Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 287,456 shares — an estimated $9.62M sold.

Aberdeen Group first reported a position in SLNO in Q4 2025 and held it in 2 quarters. The position peaked at $13.3M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Aberdeen Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Aberdeen Group sold 287,456 Soleno Therapeutics shares in Q2 2026, an estimated $9.62M.
Aberdeen Group first reported a position in Soleno Therapeutics in Q4 2025 and held it in 2 quarters.
Aberdeen Group's Soleno Therapeutics position peaked at $13.3M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.